Fed’s Powell opens door to potential rate cuts at Jackson Hole
AXT Inc . (NASDAQ:AXTI), a semiconductor materials company with a market capitalization of approximately $108 million, reported this week that it is not in compliance with Nasdaq Listing Rule 5605(c)(2)(A) following the passing of board member Christine Russell on July 11. According to InvestingPro analysis, the company currently shows a WEAK financial health score, though it maintains a healthy current ratio of 1.99x. The company disclosed in a press release statement that Ms. Russell’s death reduced the audit committee to two independent directors, below the minimum requirement of three.
Ms. Russell had served on AXT’s board since December 2019 as an independent director. She was chair of the audit committee and a member of both the compensation committee and the nominating and corporate governance committee.
On Monday, AXT notified The Nasdaq Stock Market LLC of the change. Under Nasdaq Listing Rule 5605(c)(4)(B), the company has a cure period to regain compliance, which extends until the earlier of its next annual meeting of stockholders or July 11, 2026. AXT stated it intends to add a new independent director who meets Nasdaq’s requirements before the end of the cure period.
AXT’s common stock continues to be listed on the NASDAQ Stock Market under the ticker symbol AXTI. The company is incorporated in Delaware and is headquartered in Fremont, California.
This information is based on a press release statement included in a recent SEC filing.
In other recent news, AXT Inc. reported significant developments impacting its financial outlook. The company revised its second quarter revenue guidance to between $17.5 million and $18 million, down from the previously forecasted $20 million to $22 million. This adjustment is attributed to delays in export control permits for gallium arsenide products and weaker demand in China. AXT’s first-quarter 2025 earnings also missed expectations, with an EPS of -$0.19 and revenue of $19.4 million, both falling short of analyst predictions. The company is navigating export restrictions on indium phosphide and has recently received the necessary permits to resume exports through its subsidiary, Beijing Tongmei Xtal Technology Co. Despite these challenges, AXT has announced a new equity incentive plan aimed at attracting and retaining skilled employees. Analysts from B. Riley have maintained a Buy rating on AXT, although they have slightly lowered the price target to $4.30 from $4.50. AXT is scheduled to release its full financial results for the second quarter on July 31, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.